Navigation Links
Lexicon Pharmaceuticals to Present at Bio InvestorForum
Date:10/4/2007

THE WOODLANDS, Texas, Oct. 4 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Arthur T. Sands, M.D., Ph.D., Lexicon's president and chief executive officer, will present at the BIO InvestorForum at The Palace Hotel in San Francisco, California on Thursday, October 11, 2007 at 11:00 a.m. Pacific Time.

A live webcast of Lexicon's presentation may be accessed on its corporate website at http://www.lexpharma.com. An archived version of the webcast will be available on the website through October 19, 2007.

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc. and N.V. Organon. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Amplification of genome-representative DNA from limited sources with GenomePlex WGA technology for use in genetic alterations studies
4. Wisconsin firms to present at Cleantech venture capital event
5. New Sonic Foundry search engine finds words, phrases in video presentations
6. Lone Wisconsin firm to present at InvestMidwest
7. Sonic Foundry creates search engine for 7,000 expert video presentations
8. InvestMidWest calls for business presentations
9. Wicab to present BrainPort at Boston conference
10. Three more Wisconsin firms to present at venture forum
11. Six Wisconsin firms to present at BIO Mid-America VentureForum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... Diego, CA (PRWEB) , ... August 15, 2017 ... ... company pioneering graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces the launch ... the number of steps needed to gain kinetic binding data for a wide ...
(Date:8/15/2017)... ... August 15, 2017 , ... Coffea arabica accounts ... and abiotic factors. During this educational webinar, participants will learn about the importance ... gain a better understanding of how genomics is important for coffee breeding improvement. ...
(Date:8/11/2017)... 11, 2017  Market researcher Kalorama Information ... article regarding the telemedicine market.  The telemedicine ... Information.  The article, "Heart and Asthma ...  used information from Kalorama Information,s Remote Patient ... Market  (Sleep, Diabetes, Vital Signs /EKG ...
(Date:8/10/2017)... , ... August 09, 2017 , ... ... classroom next week-- as students. From August 14th through the 16th, the University ... which debuted in the summer of 2016, provides Philadelphia-based middle school educators an ...
Breaking Biology Technology:
(Date:3/23/2017)... Research and Markets has announced the addition of the "Global ... 2025" report to their offering. ... The Global Vehicle Anti-Theft System Market is ... next decade to reach approximately $14.21 billion by 2025. ... all the given segments on global as well as regional levels ...
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/20/2017)... 20, 2017 At this year,s CeBIT Chancellor Dr. ... manufacturer DERMALOG. The Chancellor came to the DERMALOG stand together with the ... year,s CeBIT partner country. At the largest German biometrics company the two ... face and iris recognition as well as DERMALOG´s multi-biometrics system.   ... ...
Breaking Biology News(10 mins):